OBJECTIVE: Several studies haveassessed the role of adding chemotherapy to hormonaltreatment for metastatic hormone-sensitive prostatecancer (MHSPC). The objective of this manuscript is toreview these studies and to provide recommendationsfor the management of these patients.METHODS: We identified published clinical trialscomparing hormone blockade (HB) with HB plusdocetaxel as first-line treatment of HSMPC and weanalyzed their results in terms of efficacy and toxicity.RESULTS: Of the 3 trials published, two demonstratedincreased overall survival by adding docetaxel tothe first-line treatment of MHSPC (CHAARTED and Stampede-Docetaxel studies) and the third one didnot show such an advantage (GETUG-AFU15). In theCHAARTED study, the survival advantage was limitedto patients presenting high tumor volume. Toxicity wasincreased in patients who received docetaxel.CONCLUSIONS: The addition of docetaxel to treatmentwith HB should be considered in patients with MHSPC,especially in those with high tumor volume. However,the toxicity and recent results of trials performed withabiraterone in MHSPC should also be taken inconsideration.